Literature DB >> 9106014

Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes.

A Fietta1, C Merlini, G Gialdroni Grassi.   

Abstract

Determination of clarithromycin (CL) and azithromycin (AZ) uptake by human polymorphonuclear leukocytes (PMNs), monocytes and alveolar macrophages showed that AZ achieved higher levels than CL. The uptake kinetics of AZ were time-dependent over an 18 h period, while those of CL were similar to erythromycin (ER) kinetics, with a maximum level of incorporation being obtained after a 60 min incubation. The accumulation of both drugs was influenced by extracellular antibiotic-concentrations, PMN viability, extracellular calcium, physiological environmental temperature and pH. The uptake was not modified by inhibitors of cell metabolism or activators of cell membranes. After removal of extracellular antibiotic, the release of AZ from PMNs was very slow: nearly 50% of the drug remained cell-associated after 24 h incubation. The efflux of this derivative was significantly enhanced when drug-loaded PMNs were stimulated by phorbol-myristate acetate (PMA). The kinetics of CL release indicated that this macrolide behaved like ER. Nevertheless, about 10% of the initial cell-associated antibiotic showed a prolonged retention. On the whole, these data suggest that diffusion through cell membranes and trapping into acidic compartments of PMNs are important events in CL and AZ uptake.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106014     DOI: 10.1179/joc.1997.9.1.23

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  13 in total

1.  Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration.

Authors:  Diana Amantea; Michelangelo Certo; Francesco Petrelli; Giacinto Bagetta
Journal:  Assay Drug Dev Technol       Date:  2016-07-08       Impact factor: 1.738

2.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

3.  The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.

Authors:  C Miossec-Bartoli; L Pilatre; P Peyron; E N N'Diaye; V Collart-Dutilleul; I Maridonneau-Parini; A Diu-Hercend
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 5.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.

Authors:  P V Sherwood; J I D Wibawa; J C Atherton; N Jordan; D Jenkins; D A Barrett; P N Shaw; R C Spiller
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPbeta.

Authors:  Iwao Komuro; Toshiaki Sunazuka; Kiyoko S Akagawa; Yasuko Yokota; Aikichi Iwamoto; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

8.  Distribution of systemic clarithromycin to gingiva.

Authors:  Renita C Burrell; John D Walters
Journal:  J Periodontol       Date:  2008-09       Impact factor: 6.993

9.  Clarithromycin impairs tissue-resident memory and Th17 responses to macrolide-resistant Streptococcus pneumoniae infections.

Authors:  Marc Lindenberg; Luis Almeida; Ayesha Dhillon-LaBrooy; Ekkehard Siegel; Birgitta Henriques-Normark; Tim Sparwasser
Journal:  J Mol Med (Berl)       Date:  2021-02-17       Impact factor: 4.599

10.  Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Authors:  F Ratzinger; H Haslacher; W Poeppl; G Hoermann; J J Kovarik; S Jutz; P Steinberger; H Burgmann; W F Pickl; K G Schmetterer
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.